30 years of CIK cell therapy: recapitulating the key breakthroughs and future perspective

[1]  A. Rosato,et al.  Innovative therapeutic strategy for B-cell malignancies that combines obinutuzumab and cytokine-induced killer cells , 2021, Journal for ImmunoTherapy of Cancer.

[2]  Chunyan Dong,et al.  Cytokine-induced killer cells-assisted tumor-targeting delivery of Her-2 monoclonal antibody-conjugated gold nanostars with NIR photosensitizer for enhanced therapy of cancer. , 2020, Journal of materials chemistry. B.

[3]  Yutao Li,et al.  Increase of Antitumoral Effects of Cytokine-Induced Killer Cells by Antibody-Mediated Inhibition of MICA Shedding , 2020, Cancers.

[4]  I. Schmidt-Wolf,et al.  Ten‐year update of the international registry on cytokine‐induced killer cells in cancer immunotherapy , 2020, Journal of cellular physiology.

[5]  H. Lyerly,et al.  DC-CIK as a widely applicable cancer immunotherapy , 2020, Expert opinion on biological therapy.

[6]  M. Introna,et al.  Innovative Clinical Perspectives for CIK Cells in Cancer Patients , 2018, International journal of molecular sciences.

[7]  A. Rosato,et al.  Cytokines for the induction of antitumor effectors: The paradigm of Cytokine-Induced Killer (CIK) cells. , 2017, Cytokine & growth factor reviews.

[8]  Xingchun Gou,et al.  Cytokine-Induced Killer Cells As Pharmacological Tools for Cancer Immunotherapy , 2017, Front. Immunol..

[9]  H. Weiher,et al.  CIK Cells and HDAC Inhibitors in Multiple Myeloma , 2017, International journal of molecular sciences.

[10]  I. Weissman,et al.  Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity , 1991, The Journal of experimental medicine.